Agilent Technologies (A) Shares are Up 1.03%

Agilent Technologies (A) : Traders are bullish on Agilent Technologies (A) as it has outperformed the S&P 500 by a wide margin of 0.73% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.86%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.03% in the last 1 week, and is up 0.19% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 2.09% and the 50-Day Moving Average is 0.42%.The 200 Day SMA reached 10.84%

Agilent

Agilent Technologies (NYSE:A): After opening at $46.5, the stock dipped to an intraday low of $46.3 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $47.315 and the buying power remained strong till the end. The stock closed at $47.09 for the day, a gain of 1.72% for the day session. The total traded volume was 1,754,316. The stocks close on the previous trading day was $47.09.

Agilent Technologies (A) : Average target price received by Agilent Technologies (A) is $50.57 with an expected standard deviation of $3.46. The most aggressive target on the stock is $55, whereas the most downbeat target is $45. 7 financial analysts are currently covering the stock.

Agilent Technologies Inc. is engaged in the life sciences, diagnostics and applied chemical markets. The Company provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company has three business segments: the life sciences and applied markets business, the diagnostics and genomics business, and the Agilent CrossLab business. The Companys life sciences and applied markets business segment brings together the Companys analytical laboratory instrumentation and informatics. The Companys diagnostics and genomics business segment consists of three businesses: the Dako business, the genomics business and the nucleic acid solutions business. The Companys Agilent CrossLab business segment combines its analytical laboratory services and consumables business.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.